ARS Pharmaceuticals Inc.
SPRY | NASDAQ
$4.35
+$0.24 (+5.84%)
At close: Sep 21, 2026, 4:00 PM ET
$4.35
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Company Profile
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Donn Casale | CEO, President & Director |
| Richard Lowenthal MSMSEL | Co-Founder, CEO & Director |
| Alexander A. Fitzpatrick | Chief Legal Officer & Secretary |
| Kathleen D. Scott | Chief Financial Officer |
| Brian T. Dorsey | Chief Operations Officer |
| Daniel Relovsky | Senior Vice President of Marketing |
| Eric Karas | Chief Commercial Officer |
| Justin Chakma | Chief Business Officer |
| Lynda Harris | Vice President of Human Resources |
| Robert Bell | Co-Founder & Chief Science Officer |
| Sarina Tanimoto | Co-Founder & Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 02, 2026 | 4 | Filing |
| Aug 17, 2026 | 3 | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Jul 27, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 17, 2026 | 8-K | Current Report |
| Jul 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 07, 2026 | 8-K | Current Report |
| Jul 02, 2026 | 4 | Filing |
| Jun 26, 2026 | 4 | Filing |
ARS Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Dec 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 195 |
| CEO | Donn Casale |
Contact Details
11682 El Camino Real San Diego,
California 92130 United States
Stock Details
| Ticker Symbol | SPRY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671858 |
| CUSIP Number | 82835W108 |
| ISIN Number | US82835W1080 |
| SIC Code | 2834 |
Recent News
- 3 months ago / benzinga.comARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins
- 3 months ago / investors.comARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January
- 3 months ago / globenewswire.comARS Pharmaceuticals Provides Commercial and Financial Updates
Add to Watchlist
Select watchlists to add or remove SPRY